www.StockMarketingInc.com: Our Members Profit!! Undt!! Sign Up For Our Newsletter!!

STOCK MARKETING INC PRESENTS :

(OTCBB: UNDT - Universal Detection Technology) (NASDAQ: BPAX - BioSante Pharmaceuticals, Inc.) (NASDAQ: ASTE - Astec Industries, Inc.) (NASDAQ: CHTP - Chelsea Therapeutics International, Ltd.) (NASDAQ: CSCO - Cisco Systems, Inc.) (NASDAQ: DRAD - Digirad Corp.)

www.StockMarketingInc.com

To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com

email us!! info@StockMarketingInc.com

------------------------------------------------------------------------------------------------------------------------------------------------------------

(OTCBB: UNDT - Universal Detection Technology)

LATEST NEWS!!

Universal Detection Technology Anthrax Detection Equipment Approved on New York State H.I.R.E. Contract, Distributed by Strategic Response Initiatives

Post 9/11 IDIQ Contract Expedites Access to Bioterrorism Detection Equipment Recently Certified by Department of Homeland Security in New York and 14 Other States

LOS ANGELES, CA, Oct 20, 2009 -- Universal Detection Technology (www.udetection.com) (OTCBB: UNDT), a developer of early-warning monitoring technologies and counter-terrorism training programs to protect people from bioterrorism and other infectious health threats, announced yesterday that it is preparing for inclusion in the H.I.R.E. (Hazardous Incident Response Equipment) contract, a special IDIQ contract vehicle established in New York State post 9/11.

"Universal Detection Technology's addition to H.I.R.E. allows states and municipalities to quickly equip first responders and law enforcement agencies with the tools needed to combat bioterrorism threats," said Jacques Tizabi, CEO of Universal Detection Technology. "By including UNDT's handheld bio-weapons detection kits in the H.I.R.E comprehensive catalog, we are not only saving vital monetary resources and time spent on individual procurement requests, but we are also rapidly and efficiently supplying the vital resources needed to keep the public safe," continued Tizabi.

UNDT's addition to H.I.R.E. has been approved by the contract manager for New York State's Office of General Services and is pending final approval from the State's Comptroller.

As an H.I.R.E. product, Universal Detection Technology's 5 agent biodetection kits will be available through current UNDT distributor Strategic Response Initiatives, a New York based defense firm specializing in all phases of emergency preparedness planning for a wide range of defense contracts, public and private sector organizations. SRI's customers include Department of Homeland Security, U.S. State Department, U.S. Marine Corps Chemical Biological Incident Response Force (CBIRF) and NATO forces in Afghanistan.

SRI's founder and CEO Robert L. Domenici, a retired U.S. Army lieutenant colonel, is credited with charting H.I.R.E. in 2005 while he served on the WMD Task Force. Established in the wake of September 11th, H.I.R.E. addresses the problems associated with numerous individual procurement requests requiring sensitive grant money for approved products. With H.I.R.E., state and municipal entities can procure equipment without a formalized bid process, resulting in discounted manufacturer costs and a comprehensive, ready-to-order catalog contract with a variety of products, manufacturers and competitive pricing.

In addition to New York State, the contract is reciprocal in 14 other states, including California, Virginia, Massachusetts, Florida and Arizona.

Universal Detection Technology's kits, recently certified by DHS as an "Approved Product for Homeland Security" under the Support Anti-terrorism by Fostering Effective Technologies (SAFETY) Act of 2002, are the industry's only hand-held assay designed to detect and identify up to five separate threats using one sample in a single, easy-to-use device. The kits equip first responders with an effective tool for the rapid onsite detection of up to five biological warfare agents: anthrax, ricin, botulinum toxin, Y. pestis (plague) and Staphylococcal Enterotoxin B (SEB). Detection time is under three minutes.

For more information, please visit www.udetection.com or email info@udetection.com.

About Universal Detection Technology

Universal Detection Technology is a developer of monitoring technologies, including bioterrorism detection devices. The company on its own and with development partners is positioned to capitalize on opportunities related to Homeland Security. For example, Universal Detection Technology, in cooperation with NASA, has developed a bacterial spore detector that detects certain biohazard substances. The company is also a reseller of handheld assays used for detection of five bioterrorism agents, radiation detection systems, and antimicrobial products. www.udetection.com.

Forward-Looking Statements

Except for historical information contained herein, the statements in this news release are forward-looking statements that involve known and unknown risks and uncertainties, which may cause the Company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

About Strategic Response Initiatives (SRI)

Strategic Response Initiatives, LLC (SRI) was initially organized in November of 2005 as a Limited Liability Corporation providing procurement and domestic disaster preparedness training services; As a logical outgrowth of these activities, SRI now assists and supplies various military, firefighting, police, emergency medical services (EMS) and other First Responder organizations worldwide, with their critical equipment, equipment support, equipment specific training, tactical training and information technology needs.

SRI is seeking to become the leading integrator of proven and emerging technologies in the area of specialized logistics management, security assistance and training as well as environmental and disaster preparedness equipment systems and training for military, government and corporate use.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: BPAX - BioSante Pharmaceuticals, Inc.)

LATEST NEWS!!

BioSante Pharmaceuticals Reports Positive LibiGel(R) Safety Data in Phase III Program

Unblinded Data Reviewed by Independent Data Monitoring Committee (DMC)

LINCOLNSHIRE, Ill., Oct 20, 2009 -- BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), today announced positive safety data in its ongoing LibiGel Phase III clinical development program. For the first time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review of unblinded data, the DMC unanimously recommended continuation of the study as described in the study protocol, with no modifications.

BioSante reported that the DMC reviewed all unblinded adverse events in the safety study including all "serious adverse events" and all "adverse cardiovascular and breast cancer events" in 1,055 women with 883 women-years of exposure. To date, there have been no deaths, one myocardial infarction and only three breast cancers reported. Therefore, in view of the DMC recommendation, the BioSante LibiGel Phase III development program will continue as planned. BioSante targets submission to the FDA of a new drug application (NDA) by mid-2011.

"This review of unblinded LibiGel safety data by the DMC gives us even greater comfort about the safety of LibiGel," said Michael Snabes, M.D., BioSante's vice president of clinical development. "We have known, based on blinded data, that the rates of cardiovascular and breast cancer events in the study are lower than expected in women at the higher end of cardiovascular risk for the intended population. This recommendation by the DMC, after their confidential review of unblinded data, to continue the study without changes, is a validation of the safety to date of LibiGel in the treatment of female sexual dysfunction (FSD) in menopausal women, our target patient population. This outcome represents a significant advance for our LibiGel clinical development program," Dr. Snabes continued.

"The cardiovascular safety and breast cancer data indicate that LibiGel, to date, has been shown to be safe," said Stephen M. Simes, BioSante's president and CEO. "A DMC can recommend continuing, changing or stopping a study and their main responsibility is to ensure that subjects recruited to the study are not exposed to unnecessary safety risks. Therefore, the DMC's recommendation to continue the LibiGel safety study unchanged is the best possible outcome of the DMC's unblinded review of all adverse events. This is very good news for BioSante and for women since LibiGel remains the only pharmaceutical product in the U.S. in active development for the treatment of hypoactive sexual desire disorder (HSDD) in surgically menopausal women. We continue to believe that LibiGel can be the first product approved by the FDA for this common and unmet medical need, also referred to as female sexual dysfunction (FSD)."

The Phase III Cardiovascular and Breast Cancer Safety Study is a randomized, double-blind, placebo-controlled, multi-center, cardiovascular events and breast cancer study that will enroll between 2,400 and 3,100 women, exposed to LibiGel or placebo for 12 months. An NDA can be submitted and reviewed by FDA, possibly leading to approval of LibiGel, at that time. After NDA submission and potential approval of LibiGel, BioSante will continue to follow the women enrolled in the study for an additional four years.

The LibiGel safety study is tracking a predefined list of cardiovascular events, in agreement with the FDA, including cardiovascular death, myocardial infarction and stroke, in women 50 years of age or older and suffering from at least two cardiovascular risk factors including hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of cardiovascular events. The incidence of breast cancer also will be tracked over the course of the study.

In addition to the Phase III Cardiovascular and Breast Cancer Safety Study, BioSante is conducting two LibiGel Phase III efficacy trials. The Phase III efficacy trials of LibiGel in the treatment of FSD are double-blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA approved SPA (special protocol assessment agreement).

As previously announced by BioSante, treatment with LibiGel in a Phase II clinical trial significantly increased satisfying sexual events in surgically menopausal women suffering from FSD. The Phase II trial results showed LibiGel significantly increased the number of satisfying sexual events by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p<0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's lead products include LibiGel(R) (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin(TM) (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel(TM), a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook(TM)), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery. In addition, BioSante will seek opportunities for its GVAX cancer immunotherapies, which BioSante acquired from Cell Genesys, Inc. and are non patient-specific therapies comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony-stimulating factor), an immune stimulatory cytokine, and then irradiated for safety and are administered via intradermal injections on an outpatient basis. Additional information is available online at: www.biosantepharma.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often can be identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may" or the negative of these words or other words of similar meaning. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; BioSante's need for and ability to obtain additional financing; the effect of general business and economic conditions; and risks arising from BioSante's merger with Cell Genesys. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its registration statement on Form S-4 filed in connection with the merger with Cell Genesys and BioSante's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. The information set forth in this news release speaks only as of the date hereof, and BioSante undertakes no obligation to update or revise any forward looking statement, whether as a result of new information, future events or otherwise.

SOURCE: BioSante Pharmaceuticals, Inc.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: ASTE - Astec Industries, Inc.)

LATEST NEWS!!

Astec Industries Reports Third Quarter Results

CHATTANOOGA, Tenn., Oct 20, 2009 -- Astec Industries, Inc. (Nasdaq: ASTE) today reported results for its third quarter ended September 30, 2009.

Revenues for the third quarter of 2009 were $166.1 million compared with $237.4 million for the third quarter of 2008 for a 30.0% decrease. Domestic sales were $101.3 million during the third quarter of 2009 compared to $135.3 million during the third quarter of 2008. International sales were $64.8 million during the third quarter of 2009 compared to $102.1 million during the third quarter of 2008. The Company reported net income attributable to controlling interest of $3.3 million for the third quarter of 2009 compared to net income attributable to controlling interest of $16.0 million for the third quarter of 2008 for a decrease of 79.4%. Net income attributable to controlling interest for the third quarter of 2009 was $0.15 per diluted share compared to $0.71 per diluted share for the third quarter of 2008 for a 78.9% decrease.

The Company's backlog at September 30, 2009 was $144.3 million compared to $261.9 million at September 30, 2008 for a 44.9% decrease.

Consolidated financial statements for the third quarter ended September 30, 2009 and additional information related to segment revenues, profits, and backlog are attached to this press release.

Commenting on the announcement, Dr. J. Don Brock, Chairman and Chief Executive Officer, stated, "We are disappointed with our third quarter results. We experienced a continued downturn in total revenues during the third quarter. The downturn, however, is not consistent across our segments. For example, the Mobile Asphalt Paving Group third quarter revenues are up 31.5% compared to the third quarter of last year, but the Underground is down 58.1%. With these differences, we have attempted to rightsize each subsidiary and are generally pleased with the gross margins of most segments. S,G,&A expenses have been reduced, but, given the soft sales, S,G,&A is still a higher percentage of sales than our goal. We continue to aggressively develop new products with resulting higher R&D expenses."

"The failure of Congress to renew the Highway Bill creates uncertainty about future funding impacting capital equipment purchasing behavior. Additionally, continued softness in the residential and commercial real estate markets is resulting in the under utilization of customer equipment and less need for additional or replacement equipment. The stimulus packages passed earlier in the year are clearly helping the Mobile Asphalt Paving Group and other segments, but are not enough to counter the continuing economic downturn and the uncertainty around the Highway Bill. Until Congress settles on a new Highway Bill, we expect to see little improvement in domestic sales during the fourth quarter of 2009 and next year."

"International sales declined in total dollars and as a percentage of total sales. Nonetheless, more than 50% of our September 30 backlog is international orders. Approximately 25 foreign countries have instituted stimulus packages and the weak U.S. dollar should favorably impact international sales."

Dr. Brock continued, "Visibility in the market and trends is very limited. The fourth quarter is normally our least profitable quarter of the year. We will manage the company for the long-term and control costs. We have no debt and $36 million of cash and cash equivalents, and will continue to manage our assets. Our strong balance sheet gives us the opportunity to develop new products and to consider acquisitions as they become available."

Investor Conference Call and Web Simulcast

Astec will conduct a conference call on October 20, 2009, at 10:00 A.M. Eastern Time to review its third quarter results as well as current business conditions. The number to call for this interactive teleconference is (877) 407-9210. International callers should dial (201) 689-8049. Please reference Astec Industries.

The company will also provide an online Web simulcast and rebroadcast of the conference call. The live broadcast of Astec's conference call will be available online at the Company's website: www.astecindustries.com/conferencecalls. An archived webcast will be available for 90 days at www.astecindustries.com.

A replay of the conference call will be available through midnight on Tuesday, November 3, 2009, by dialing (877) 660-6853, or (201) 612-7415 for international callers, Account #286, Conference ID# 335140. A transcription of the conference call will be made available under the Investor Relation section of the Astec Industries, Inc. website within 5 days after the call.

Astec Industries, Inc. is a manufacturer of specialized equipment for building and restoring the world's infrastructure. Astec's manufacturing operations are divided into four business segments: aggregate processing and mining equipment; asphalt production equipment; mobile asphalt paving equipment; and underground boring, directional drilling and trenching equipment. Astec also has a company engaged in the wood chipping and grinding industry.

The information contained in this press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the future performance of the Company, including statements about the Company's financial performance for 2009, the ability to control costs and maintain or improve margins, the state of the U.S. economy, the effect of a renewed Highway Bill, increases in demand for certain products, the effect of domestic and international stimulus packages, the continued strength or weakness of various business units, and international sales. These forward-looking statements reflect management's expectations and are based upon currently available information, and the Company undertakes no obligation to update or revise such statements. These statements are not guarantees of performance and are inherently subject to risks and uncertainties, many of which cannot be predicted or anticipated. Future events and actual results, financial or otherwise, could differ materially from those expressed in or implied by the forward-looking statements. Important factors that could cause future events or actual results to differ materially include: general uncertainty in the economy, downturns in the general economy or the commercial construction industry, the cyclical nature of the commercial, construction industry and the customization of the equipment the Company sells, increases in the price of oil or decreases in the availability of oil, increases in the price of raw materials, a failure to comply with covenants in the Company's credit agreement, contingent liability for certain customer debt, rising interest rates, rising steel and steel component pricing, delayed or decreased funding for highway construction and maintenance, increased government regulation, managing and expanding in international markets, the timing of large contracts, the costs of introducing new equipment systems, the Company's production capacity, demand for the Company's products, seasonality of sales volumes, competitive activity and those other factors listed from time to time in the Company's reports filed with the Securities and Exchange Commission, including but not limited to the Company's annual report on Form 10-K for the year ended December 31, 2008.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: CHTP - Chelsea Therapeutics International, Ltd.)

LATEST NEWS!!

Chelsea Therapeutics Presents Novel, Metabolically Inert Autoimmune Portfolio at the 2009 ACR Annual Scientific Meeting

CHARLOTTE, N.C., Oct 20, 2009 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) will present results from Chelsea's two clinical stage product candidates in its portfolio of metabolically inert antifolate molecules at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting in Philadelphia, Pennsylvania. The presentations will include previously reported results from a Phase II, proof-of concept study of CH-1504 and a Phase I trial of CH-4051.

Dr. Edward Keystone, M.D., FRCP(C), Professor of Medicine, Rheumatology Division at The University of Toronto, Canada, and principal investigator for the study, will present detailed findings from Chelsea's 12-week proof-of-concept study in methotrexate (MTX) naive rheumatoid arthritis (RA) patients. The findings demonstrate that CH-1504 has comparable efficacy to MTX and may be safer and better tolerated. In addition to Dr. Keystone's platform presentation, Chelsea will present safety, tolerability and pharmacokinetic data from its recently completed Phase I trial of CH-4051, the more potent "L" isomer of the racemic mixture CH-1504.

Chelsea's novel, orally available and metabolically inert antifolate compounds are engineered to have potent autoimmune, anti-inflammatory and anti-tumor properties. These compounds may potentially be used to treat such diseases as rheumatoid arthritis, psoriasis, inflammatory bowel disease, cancer and other immunological disorders. Additionally, they are metabolically inert and therefore believed to have fewer harmful and unpleasant side effects than those typically associated with classical antifolates such as MTX, currently the standard of care for a broad range of abnormal cell proliferation diseases.

Both CH-1504 and CH-4051 inhibit dihydrofolate reductase, an enzyme required for cell proliferation. However, due to their lack of metabolism, the compounds appear to be devoid of the liver and kidney toxicities related to the formation of the metabolites and observed with long-term use of MTX.

Presentation Details are as follows:

Title: CH-1504, a Metabolically Inert Antifolate, Is An Effective and Well-Tolerated Treatment for Patients with Moderate to Severe Rheumatoid Arthritis Session: Rheumatoid Arthritis Therapy: Novel Therapies in the Pipeline Date/Time: Tuesday, October 20, 2009 at 3:45 PM Eastern Time Presentation: 1927 Location: Auditorium - Pennsylvania Convention Center Title: Phase I Single and Multiple Ascending Dose Studies to Investigate the Safety, Tolerance and Pharmacokinetics of CH-4051 in Healthy Male Subjects Session: Rheumatoid Arthritis Treatment: Steroids, Methotrexate, and Novel Targets Date/Time: Sunday, October 18, 2009 from 9:00 AM - 11:00 AM Eastern Time Poster: 431 Location: Hall D - Pennsylvania Convention Center

About Chelsea Therapeutics

Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea's most advanced drug candidate, Droxidopa, is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. In addition to Droxidopa, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior safety and tolerability, as well as increased potency versus methotrexate (MTX).

This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include our need to raise operating capital, our history of losses, risks and costs of drug development, risk of regulatory approvals, our reliance on our lead drug candidates Droxidopa and CH-1504, reliance on collaborations and licenses, intellectual property risks, competition, market acceptance for our products if any are approved for marketing and reliance on key personnel including specifically Dr. Pedder.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: CSCO - Cisco Systems, Inc.)

LATEST NEWS!!

Cisco Ushers in Borderless Networks Era With Next Generation of the Integrated Services Router

Cisco Integrated Services Router Generation 2 Helps Businesses Deploy On-Demand Video, Mobility, Security, and Other Services to Achieve Greater Cost Savings SAN JOSE, CA, Oct 20, 2009 -- To address evolving information technology (IT) needs around increasingly distributed and collaborative workforces, Cisco (NASDAQ: CSCO) today introduced its Borderless Networks architecture and a five-phase plan designed to help deliver services and applications to anyone, anywhere, on any device, at anytime -- seamlessly, reliably, and securely. As the first proof point of its Borderless Networks architecture, Cisco announced the second generation of its Integrated Services Router, the ISR G2.

The Cisco ISR G2 helps businesses and service providers simplify and scale delivery of on-demand, networked business services like video and collaborative applications at branch offices. It serves as a natural part of the company's Borderless Networks architecture, which combines Cisco's routing, switching, wireless, and security technologies into a more tightly integrated networking infrastructure that allows businesses to embrace the growing use of video, collaborative applications, and other networked services and deliver them across their enterprises. With Borderless Networks, information technology managers can more easily manage, scale, govern, and protect networks while tightening the synergy between users, devices, applications, and business processes.

Highlights:

The Cisco ISR G2 portfolio is built on the company's 25-year routing heritage. It offers as much as five times the performance of its predecessor, the Cisco ISR, the industry's most widely deployed router with more than 7 million units sold since its introduction in 2004.

-- Business video - With business video adoption expected to climb to 77.6 percent by 2012 (Cisco VNI Research), and with video proven to play a key role in enabling business innovation and better customer service, the video-ready architecture and new video digital signal processors in the ISR G2 will be key to delivering medianet capabilities essential to the borderless networks experience.

-- Service virtualization with an "on-demand" service delivery - Borderless Networks solutions decouple hardware and software so that virtual services can be remotely deployed and managed. The ISR G2 implements this with the innovative Services-Ready Engine, which lets businesses dynamically deploy services in branches without costly onsite support. The ISR G2 Services Module comes with up to 1 terabyte of on-board storage, which is useful for video surveillance deployments, and supports up to seven times the performance of previous network modules.

-- Operational savings - The Borderless Networks architecture delivers Cisco EnergyWise across multiple platforms to enable organizations to better manage their power consumption and costs through increased visibility and policy-based controls. ISR G2 extends this capability to the branch office with a new family of integrated EnergyWise compliant switch modules and slot-based power control.

-- The borderless experience - The Borderless Networks architecture breaks down boundaries between location, device, and application. As applications and services are increasingly offered and consumed from beyond the enterprise perimeter, a new approach will be required. The ISR G2 enables sophisticated premise-based services while extending mobility, security, and performance to users, no matter where the user or application is located.

Product Highlights:

The Cisco ISR G2 is a full portfolio of routers designed to cost effectively deliver a range of concurrent services and applications ranging from virtual office solutions, mobility, customizable applications, collaboration, and ultimately to scalable rich-media services like Cisco Telepresence(TM), video streaming and digital signage, all with industry-leading security.

-- Cisco 3900 Series Integrated Services Router: The flagship of the ISR G2 portfolio, these routers provide high availability, investment protection, performance and scalability. At the same time they offer unparalleled total cost of ownership savings and network agility through the intelligent integration of market-leading security, switching, unified communications, video, wireless, WAN optimization and application services.

-- Cisco 2900 Series Integrated Services Router: The midrange of the ISR G2 portfolio offers superior value by delivering market-leading security, switching, unified communications, video, wireless, and application services, while providing cost-effective industry-leading investment protection.

-- Cisco 1900 Series Integrated Services Router: The Cisco 1941 is a compact-modular router delivering a broad set of connectivity options including new 802.11n wireless local-area network capabilities, in addition to market-leading services such as security, switching and wireless all in a desktop form factor.

-- Cisco IOS(R)(TM) Release 15: The ISR G2 portfolio ships with Cisco IOS Release 15.0(1)M, a new software version delivering enhanced security, voice, manageability and IP services for a more consistent user experience and improved operational efficiency. A single universal image with license-based activation simplifies operations and feature selection through easy software management, enabling faster deployment of Borderless Networks services. A trial software license is also available.

-- Building medianet technologies: The ISR G2 series is medianet-ready, helping businesses and service providers to optimize the delivery of rich-media applications. Cisco is also launching the Enterprise Medianet Foundation Architecture to help enable rich-media collaboration. Powered in part by the ISR G2, medianets will deliver the next generation of video experiences resulting from high-definition video and innovative rich-media applications.

-- Related customer training: To help customers capitalize on the ISR's new medianet video-enablement capabilities, Learning@Cisco is introducing advanced technology skill-building products for IT professionals working with Cisco video and collaboration technologies.

Scheduled to be available in late 2009, these new certification and training products will provide classroom and online enablement opportunities for designing, implementing, and configuring video and medianet solutions.

-- ASR 1002-F Router: Cisco is also introducing a new platform for its Aggregation Services Router -- the ASR 1002-F, delivering small-scale highly secure WAN aggregation and private WAN and Internet Edge for Borderless Networks. The new Cisco ASR 1002-F router is a fixed-configuration version of the ASR 1000 Series.

Supporting Quotes:

-- Brett Galloway, senior vice president for Cisco's Wireless, Security and Routing Technology Group: "Networking has always been at the core of Cisco's business. We have a long history of excellence and innovation in networking and we continue to bring customers new capabilities, including new technologies enabling video, collaboration, virtualization and mobility. Our ISR G2 router line significantly increases our customers' ability to capitalize on these key business and technology trends. Our core networking business remains as strategic and as vitally important to us, as it does to those we serve." -- Richard Palmer, senior vice president for Cisco's Access Routing Group: "Building on Cisco's branch office heritage, the Cisco Integrated Services Router Generation 2 delivers a borderless network experience through service virtualization, new video-ready capabilities and operational excellence. High-performance, secure collaboration across time zones and devices with rich-media services will allow businesses to meet changing needs and increase employee productivity." -- Mike Marcellin, vice president - global managed solutions, Verizon: "As companies look to grow their business, many are focused on delivering new IP-enabled capabilities, such as video, to all of their corporate locations. The Cisco ISR G2 delivers multi-function capabilities to support the needs of today's highly-distributed enterprise, especially retailers that are using new applications to build store traffic and brand loyalty. Building on its long history of working closely with Cisco, Verizon Business will offer a managed version of this new platform that will centralize ongoing support and management. By coupling the features of Cisco's next-generation global ISR with Verizon's extensive managed services expertise, enterprises will benefit from a low-touch, all-in-one solution." -- Sean Burke, vice president of network operations, inVentiv Health: "The new ISR G2 series is a significant leap forward, with integrated video-ready and voice services, robust security, as well as the ability to easily deploy new capabilities as needed with the Services Ready Engine. inVentiv's ISR deployment allows worldwide employee and customer collaboration with voice, data and video capabilities, and our Cisco WAAS deployment dramatically speeds application delivery for high-definition video, large data transfers, and other collaboration applications. The addition of Cisco EnergyWise on the ISR G2 EtherSwitch module will allow for dramatically lower energy costs as well."

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: DRAD - Digirad Corp.)

LATEST NEWS!!

Digirad Corporation to Present at BIOCOM 4th Annual Investor Conference

POWAY, Calif., Oct 20, 2009 -- Digirad Corporation (Nasdaq: DRAD) announced today that Chief Executive Officer Todd Clyde is scheduled to make an investor presentation at the BIOCOM 4th Annual Investor Conference at 12:00 pm PDT on Monday, October 26. The conference will be held at the Hyatt Regency La Jolla Hotel in San Diego, CA October 26-27.

The presentation with slides will include a discussion of Digirad's business, strategic focus and outlook. The presentation will be webcast live on the events and presentation page of the investors section of Digirad's web site at www.digirad.com. An archive of the presentation will be accessible at this site for 90 days.

About Digirad Corporation

Digirad is a leading provider of diagnostic imaging products, and personnel and equipment leasing services to physicians' offices, hospitals and imaging centers. For more information, please visit www.digirad.com. Digirad(R), Digirad Imaging Solutions(R), and Cardius(R) are registered trademarks of Digirad Corporation.

------------------------------------------------------------------------------------------------------------------------------------------------------------

About StockMarketingInc.com

StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

CONTACT: StockMarketingInc.com e-mail: info@StockMarketingInc.com Tel: +1 866 583 8960

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: acquisition, adoption, afghanistan, annual report, anthrax, architecture, arizona, arthritis, breast cancer, business, business services, california, canada, cancer, cardiovascular, ceo, clinical, commercial, communications, conference, congress, construction, contraception, contract, corporate, debt, defense, defense contracting, diabetes, disease, distributor, economy, email, e-mail, emergency, energy, fda, florida, foundation, government, hardware, health, homeland security, hotel, information technology, interest rates, internet, investment, investment opinion, law enforcement, leasing, licenses, local, manufacturer, manufacturing, marine, market, marketing, massachusetts, medical, medicine, menopause, merger, military, mining, money, nasa, nasdaq, nato, networking, new york, oil, online, pennsylvania, pharmaceuticals, physicians, police, policy, population, president, productivity, products, profit, property, real estate, research, sales, securities, security, software, steel, swine, technology, tennessee, terrorism, toronto, traffic, training, trial, us dollar, vaccine, video, virginia, weapons, web, wireless, women